Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Surg Case Rep ; 7(1): 153, 2021 Jun 29.
Artículo en Inglés | MEDLINE | ID: mdl-34185178

RESUMEN

BACKGROUND: Cap polyposis (CP) is extremely rare in Japan, and there is no established cure. We report a case in which CP was improved by surgical treatment. CASE PRESENTATION: A 48-year-old man was investigated at a local hospital because of diarrhea and bloody stools in 2018. The patient was treated with metronidazole for suspected amoebic dysentery, but his symptoms did not improve. Subsequent close examination revealed possible CP, but treatment with 5-aminosalicylic acid and a steroid enema had no effect. The patient was then referred to our hospital. The bloody stools, diarrhea, and abdominal pain worsened despite medical treatment, so laparoscopic-assisted total proctocolectomy and ileal J-pouch anal anastomosis with ileostomy were performed. CP has no known cause or established treatment, but Helicobacter pylori (HP) infection has been reported in many CP cases in Japan, and HP eradication is often successful. This patient was HP-negative and did not improve with antimicrobial treatment, but the symptoms improved after surgery. CONCLUSIONS: Even after surgery, CP recurrence reportedly occurs within a short period in many cases. However, our patient has had no signs of CP recurrence during 1 year of follow-up.

2.
Int J Urol ; 25(5): 479-485, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29577437

RESUMEN

OBJECTIVES: To assess the effect of cernitin pollen extract on serum prostate-specific antigen level prostate biopsy candidates, and to develop an ideal protocol to avoid an unnecessary biopsy procedure. METHODS: A total of 61 patients were administrated cernitin pollen extract tablets (two tablets t.i.d.) for 30 days, and then underwent a prostate biopsy with ≥12 systematic and targeted biopsy cores obtained. Serum prostate-specific antigen levels were examined before and after administration of the pollen extract, and the change in serum prostate-specific antigen and the rate of change were analyzed in relation to negative and positive biopsy results for cancer. RESULTS: The mean change in serum prostate-specific antigen and rate of change after administration of cernitin pollen extract in all patients were -0.6 ± 1.4 ng/mL and -7.6 ± 16.1%, respectively, which were significantly different from the baseline values (P = 0.0003 and P = 0.0005, respectively). When prostate-specific antigen change values and rates were compared between patients negative and positive for cancer, a significant difference between those groups was observed (P = 0.04 and P = 0.03, respectively). CONCLUSIONS: The present study is the first to show that an ideal protocol using cernitin pollen extract has the potential to avoid an unnecessary prostate biopsy procedure in patients with elevated prostate-specific antigen, possibly caused by inflammation. Additional studies with greater numbers of participants are required to confirm our findings and develop an ideal protocol.


Asunto(s)
Extractos Vegetales/administración & dosificación , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/diagnóstico , Prostatitis/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Biopsia/efectos adversos , Humanos , Japón , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Próstata/patología , Neoplasias de la Próstata/patología , Curva ROC , Secale , Procedimientos Innecesarios
3.
Nihon Shokakibyo Gakkai Zasshi ; 115(2): 211-218, 2018.
Artículo en Japonés | MEDLINE | ID: mdl-29459565

RESUMEN

A 16-year-old woman identified with colonic distention using chest X-rays visited our hospital. Although abdominal computed tomography (CT), colonoscopy, and barium enema study indicated suspected duplication of the sigmoid colon, the exact portion of communication between the normal colon and the duplicated colon could not be determined. The patient was released, but followed up due to the lack of symptoms. After 7 months, she was urgently re-hospitalized due to the complaint of abdominal pain. Her abdominal CT revealed the wall thickness and distention of the duplication as well as voluminous stool containing barium. After the improvement of her symptoms and on the basis of the inflammatory findings, laparoscopic surgery was performed on the patient. Finally, the lesion was diagnosed as tubular- and continuous-type colonic duplication. Duplication of the colon is a relatively rare occurrence in adulthood. Herein, we report a case of duplication of the sigmoid colon diagnosed prior to surgery in an adult.


Asunto(s)
Colon Sigmoide/diagnóstico por imagen , Laparoscopía , Adolescente , Adulto , Colon Sigmoide/patología , Colonoscopía , Femenino , Humanos , Radiografía , Tomografía Computarizada por Rayos X
4.
Nagoya J Med Sci ; 79(2): 273-277, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-28626263

RESUMEN

Choline is a new PET tracer, which uptake may occur via a choline-specific transporter protein and be accelerated during the proliferation of tumor cells. We report a 61-year-old woman with a metastatic pancreatic tumor from renal cell carcinoma, measuring 35×40 mm. PET scans demonstrated accumulation of 11C-choline in the metastatic pancreatic tumor, but no accumulation of 18F-FDG. Choline PET/CT may play a useful and complementary imaging modality, especially when FDG-PET/CT does not show expected findings or when the evaluation of tumor viability is needed, in patients with renal cell carcinoma.


Asunto(s)
Carcinoma de Células Renales/tratamiento farmacológico , Colina/química , Fluorodesoxiglucosa F18/análisis , Neoplasias Renales/tratamiento farmacológico , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Carcinoma de Células Renales/complicaciones , Femenino , Humanos , Neoplasias Renales/complicaciones , Persona de Mediana Edad
5.
Cancer Res Treat ; 48(4): 1155-1166, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27384163

RESUMEN

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.


Asunto(s)
Manejo de la Enfermedad , Tumores del Estroma Gastrointestinal/diagnóstico , Tumores del Estroma Gastrointestinal/terapia , Terapia Molecular Dirigida , Pueblo Asiatico/genética , China , Consenso , Tumores del Estroma Gastrointestinal/patología , Guías como Asunto , Humanos , República de Corea , Taiwán
6.
Gastric Cancer ; 19(1): 3-14, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26276366

RESUMEN

Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines--for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry--their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus.


Asunto(s)
Neoplasias Gastrointestinales/diagnóstico , Neoplasias Gastrointestinales/terapia , Tumores del Estroma Gastrointestinal/diagnóstico , Tumores del Estroma Gastrointestinal/terapia , Antineoplásicos/uso terapéutico , Resistencia a Antineoplásicos , Estudios de Seguimiento , Neoplasias Gastrointestinales/epidemiología , Tumores del Estroma Gastrointestinal/epidemiología , Humanos , Mesilato de Imatinib/uso terapéutico , Mutación , Recurrencia Local de Neoplasia , Compuestos de Fenilurea/uso terapéutico , Guías de Práctica Clínica como Asunto , Proteínas Proto-Oncogénicas c-kit/genética , Piridinas/uso terapéutico
7.
Int J Clin Oncol ; 13(5): 416-30, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18946752

RESUMEN

Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved greatly since the introduction of molecularly targeted therapies. Although several clinical practice guidelines are extant, such as those published by the National Comprehensive Cancer Network and the European Society of Medical Oncology, it is not clear as to whether these are appropriate for clinical practice in Japan. Therefore, clinical practice guidelines for the optimal diagnosis and treatment of GIST tailored for the Japanese situation have often been requested. For this reason, the Japanese Clinical Practice Guideline for GIST was proposed by the GIST Guideline Subcommittee, with the official approval of the Clinical Practice Guidelines Committee for Cancer of the Japan Society of Clinical Oncology (JSCO), and was published after assessment by the Guideline Evaluation Committee of JSCO. The GIST Guideline Subcommittee consists of members from JSCO, the Japanese Gastric Cancer Association (JGCA), and the Japanese Study Group on GIST, with the official approval of these organizations. The GIST Guideline Subcommittee is not influenced by any other organizations or third parties. Revision of the guideline may be done periodically, with the approval of the GIST Guideline Subcommittee, either every 3 years or when important new evidence that might alter the optimal diagnosis and treatment of GIST emerges. Here we present the English version of the Japanese Clinical Practice Guideline for GIST prepared by the GIST Guideline Subcommittee.


Asunto(s)
Tumores del Estroma Gastrointestinal/diagnóstico , Tumores del Estroma Gastrointestinal/terapia , Algoritmos , Antineoplásicos/uso terapéutico , Benzamidas , Diagnóstico por Imagen , Resistencia a Antineoplásicos , Tumores del Estroma Gastrointestinal/cirugía , Humanos , Mesilato de Imatinib , Mutación , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Piperazinas/uso terapéutico , Proteínas Proto-Oncogénicas c-kit/genética , Pirimidinas/uso terapéutico
8.
J Exp Med ; 196(7): 979-90, 2002 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-12370259

RESUMEN

We generated a mouse line in which the src homology 2 domain-bearing protein tyrosine phosphatase (SHP)-2 binding site of gp130, tyrosine 759, was mutated to phenylalanine (gp130(F759/F759)). The gp130(F759/F759) mice developed rheumatoid arthritis (RA)-like joint disease. The disease was accompanied by autoantibody production and accumulated memory/activated T cells and myeloid cells. Before the disease onset, the T cells were hyperresponsive and thymic selection and peripheral clonal deletion were impaired. The inhibitory effect of IL-6 on Fas ligand expression during activation-induced cell death (AICD) was augmented in gp130(F759/F759) T cells in a manner dependent on the tyrosine residues of gp130 required for signal transducer and activator of transcription 3 activation. Finally, we showed that disease development was dependent on lymphocytes. These results provide evidence that a point mutation of a cytokine receptor has the potential to induce autoimmune disease.


Asunto(s)
Artritis Experimental/inmunología , Receptores de Interleucina-6/genética , Linfocitos T/inmunología , Tirosina , Sustitución de Aminoácidos , Animales , Formación de Anticuerpos , Apoptosis , Artritis Experimental/genética , Artritis Experimental/patología , Secuencia de Bases , Sitios de Unión , Huesos/patología , Linfocitos T CD4-Positivos/inmunología , Cartilla de ADN , Enterotoxinas/inmunología , Ganglios Linfáticos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mutación Puntual , Reacción en Cadena de la Polimerasa , Subunidades de Proteína , Staphylococcus aureus/inmunología , Superantígenos/inmunología , Linfocitos T/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA